INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
105 hedge funds and large institutions have $145M invested in Inozyme Pharma in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
5.46% less ownership
Funds ownership: 87.02% → 81.56% (-5.5%)
49% less capital invested
Capital invested by funds: $286M → $145M (-$140M)
53% less call options, than puts
Call options by funds: $7K | Put options by funds: $15K
Holders
105
Holding in Top 10
2
Calls
$7K
Puts
$15K
Top Buyers
| 1 | +$3.19M | |
| 2 | +$1.57M | |
| 3 | +$890K | |
| 4 |
Renaissance Technologies
New York
|
+$711K |
| 5 |
Walleye Capital
New York
|
+$658K |
Top Sellers
| 1 | -$17M | |
| 2 | -$5.3M | |
| 3 | -$1.81M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.42M |
| 5 |
Goldman Sachs
New York
|
-$539K |